Powered by: Motilal Oswal
01-01-1970 12:00 AM | Source: ICICI Securities Ltd
Buy EPL Ltd For Target Rs.240 - ICICI Securities
News By Tags | #872 #1488 #57 #3518 #937 #1302

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

Gold Medal by EcoVadis – an advantage

EPL’s Q4FY23 print has shown sequential improvement in EBITDA margin; however, it is still far away from normal. We believe FY24 could potentially have exponential recovery with demand normalising across geographies, selective price increases, ramp up in Brazil operation and stable inflation. EPL has shown remarkable growth in sustainable tubes (2.5x in FY23) which is aiding it to grab a higher tube market share and this phenomenon should only accelerate. Gold Medal certificate by EcoVadis rating puts EPL in an advantageous position in sustainable tubes which has been the highest-priority area for the entire FMCG customer base of EPL. We expect EPL’s EBITDA and net profit CAGR of 20% and 29%, respectively, over FY23-25E which should also drive higher FCF / dividend. We have tweaked our EPS estimates for FY24 / FY25. We are changing our valuation methodology from DCF to P/E multiple. Accordingly, we derive a TP of Rs240 (prior: Rs220) valuing the company at 20x FY25E EPS. Maintain BUY

 

* Revenue up 10.1% YoY to Rs9.7bn. Revenue growth was aided by improvement in EAP, up 8.6% YoY, easing lockdown in China, and strong growth in the Americas and Europe where revenues were up 17.1% and 19.9% YoY, respectively. EPL is selectively taking price increases in developed markets to pass on higher operating cost which will help revenue and margins in FY24. AMESA’s revenue grew 7.6% YoY, and was impacted by currency depreciation in Egypt; adjusted for Egypt revenue, it grew 15% YoY. Brazil has commenced production and the company expects ramp up in Q1FY24 which will likely further aid revenue. Oral care revenue rose 16.6% YoY to Rs4.9bn. Personal care segment was up 8.2% YoY to Rs4.1bn. Beauty & cosmetics showed growth of 19.6% YoY; pharmaceutical revenue was up 12.6% YoY and ‘others’ was down 9.9% YoY. Laminate revenue declined 12.7% YoY to Rs750mn.

 

* Gross margin dipped 80bps QoQ to 54.0%. Gross profit was up 10.2% YoY to Rs5.2bn. Despite lower raw material prices, margin dropped on change in product and geographical mix. Employee and other expenses have grown 9.8% and 6.2% YoY; EPL continues to be hurt from rise in minimum wages and higher power cost in Europe. EBITDA grew 16.2% to Rs1.5bn and was impacted by Brazil establishment cost. EBITDA margin improved 10bps QoQ to 15.9%. In FY24, EBITDA margin should benefit from price increases and Brazil may become a margin-accretive business. Other income benefited from grants and EPL had tax rebate in Q4FY23. PAT grew 73% YoY to Rs0.8bn.

 

Geography-wise performance. 1) AMESA’s revenue rose 7.6% YoY to Rs3.4bn; EBITDA was up 41.0% YoY to Rs805mn, and EBITDA margin was up 310bps QoQ to 23.8%. 2) EAP revenue rose 8.6% YoY (dip 5.4% QoQ) to Rs2.1bn; EBITDA rose 32.6% YoY to Rs386mn with EBITDA margin decline of 360bps QoQ to 18%. 3) Revenue from Americas increased 17.1% YoY to Rs2.3bn, but EBITDA dipped 17.4% YoY to Rs257mn. EBITDA margin was down 90bps QoQ to 11.2%. 4) Europe revenue rose 19.9% YoY to Rs2.5bn; EBITDA was up 14.3% YoY to Rs288mn and EBITDA margin expanded to 11.5% from lows (5.7%) of Q3FY23

 

 

To Read Complete Report & Disclaimer Click Here

 

For More ICICI Securities Disclaimer https://www.icicisecurities.com/AboutUs.aspx?About=7

 

Above views are of the author and not of the website kindly read disclaimer